Chuong Huynh

Chuong Huynh serves as a key procurement professional within the Administration for Strategic Preparedness and Response (ASPR), supporting the agency’s mission to ensure national readiness for public health emergencies through the strategic acquisition of biomedical countermeasures and advanced research capabilities. Responsible for managing complex acquisition cycles, Huynh specializes in procuring research and development services critical to pandemic preparedness, diagnostic innovation, and biodefense technologies. Their work directly enables ASPR’s mandate to sustain a resilient biomedical industrial base by accelerating the transition of scientific breakthroughs into scalable, deployable solutions for federal response operations. Huynh collaborates with a diverse ecosystem of biotechnology firms, academic research institutions, and contract research organizations that possess specialized expertise in molecular diagnostics, vaccine platform development, and therapeutic candidate screening. While no single contractor dominates their portfolio, Huynh consistently engages with entities capable of meeting stringent regulatory and manufacturing readiness requirements under BARDA and other ASPR programs. Relationships are built on technical rigor, rapid prototyping capacity, and compliance with federal biomanufacturing standards, with a focus on agile, milestone-driven contracting approaches. Huynh’s contracting patterns reflect a strong preference for open competition, with 100% of procurements classified as “No Set-Aside.” This indicates a strategic emphasis on technical merit and operational readiness over socioeconomic categorization, prioritizing capability and speed over traditional small business set-asides such as 8(a), HUBZone, or SDVOSB programs. While small businesses are not excluded, the procurement strategy is driven by mission-critical performance needs rather than socioeconomic targeting. The primary NAICS classification under Huynh’s purview is 541714—Research and Development in Biotechnology—reflecting deep specialization in preclinical and translational biomedical innovation. Procurements center on high-complexity R&D services including target validation, antibody engineering, biocontainment testing, and platform technology development for next-generation countermeasures against emerging pathogens and chemical threats. Their expertise lies at the intersection of federal acquisition regulation, biotech innovation cycles, and public health emergency response timelines.